.png)
On 3 January, the Drugs Controller General of India (DCGI) approved Bharat Biotech-ICMR's ‘Covaxin’ and Oxford-AstraZeneca’s 'Covishield' vaccine for restricted use in emergency situation.
"We'll never approve anything if there is slightest of safety concern. The vaccines are 110 per cent safe. Some side effects like mild fever, pain and allergy are common for every vaccine. It (that people may get impotent) is absolute rubbish," Drug Controller General of India VG Somani said.
“After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of Serum and Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to Cadila Healthcare for conduct of the Phase III clinical trial,” he said.
AIIMS Director Dr Randeep Guleria said that both the vaccines are cost-effective and easy to administer.
Both the vaccines have to be administered in two doses. All the vaccines have to be stored at a temperature of 2-8 degree celsius. The government has already said that it will give priority to 1 crore healthcare workers and 2 crore frontline workers when the vaccinations begin.
Source: NDTV
.png)
Thank you for your comment